Blue is good for Bluebird as it snags "blue chip" $60m
This article was originally published in Scrip
Executive Summary
Bluebird Bio raised $60 million in Series D financing to advance its novel approach to gene therapy for severe genetic disorders, which involves the insertion of healthy versions of disease-causing genes into stem cells harvested from a patient's bone marrow.